Drug-eluting stents increased risk for late cardiac death or myocardial infarction more than bare-metal stents

Pfisterer, M.; Brunner-La Rocca, H. P.; Buser, P. T.
May 2007
ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p67
Academic Journal
The article presents a study which examines the effectiveness of drug-eluting stents (DES) versus bare-metal stents (BMS) in patients with coronary artery disease who discontinue anti-platelet therapy. Results revealed that DES lessen the risk of having major cardiac events. It is concluded that the increased risk of late cardiac death following the discontinuation of antiplatelet clopidogrel therapy may offset the early benefits of drug-eluting stents over bare-metal stents.


Related Articles

  • Review: Drug-eluting stents for coronary artery disease do not reduce mortality more than bare-metal stents. Nordmann, A. J.; Briel, M.; Bucher, H. C. // ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p66 

    The article examines a study which compares the effectiveness of drug-eluting (DES) stents versus bare metal stents (BMS) in treating patients with coronary artery disease. Results revealed that DES and BMS did not differ in terms of total mortality or cardiac mortality at any follow-up...

  • Review: Drug-eluting stents for coronary artery disease do not reduce mortality more than bare-metal stents: COMMENTARY. Bates, Eric R. // ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p66 

    The author comments on a study which compares the effectiveness of drug-eluting (DES) stents versus bare metal stents (BMS) in patients with coronary artery disease. He asserted that the meta-analysis by researchers used to support DES labeling has indicated no long-term increase in death of...

  • Determinants of the Efficacy of Cardiac Ischemic Preconditioning: A Systematic Review and Meta-Analysis of Animal Studies. Wever, Kimberley E.; Hooijmans, Carlijn R.; Riksen, Niels P.; Sterenborg, Thomas B.; Sena, Emily S.; Ritskes-Hoitinga, Merel; Warlé, Michiel C. // PLoS ONE;11/18/2015, Vol. 10 Issue 11, p1 

    Background: Ischemic preconditioning (IPC) of the heart is a protective strategy in which a brief ischemic stimulus immediately before a lethal ischemic episode potently limits infarct size. Although very promising in animal models of myocardial infarction, IPC has not yet been successfully...

  • Stenting of the Unprotected Left Main Coronary Artery in a Nonagenarian Presenting with Recurrent Non-ST Elevation Myocardial Infarction. Raizada, Amol; Petrasko, Marian; Stys, Tomasz P.; Stys, Adam T. // South Dakota Medicine;Jul2014, Vol. 67 Issue 7, p265 

    Coronary artery disease (CAD) involving the left main (LM) artery has traditionally been considered an indication for coronary artery bypass surgery (CABG). With recent advances in the field of percutaneous coronary interventions (PCI), angioplasty and stenting of the unprotected' LM has been...

  • FDA cleared zotarolimus-eluting stent for use in coronary arteries. Borden, William E. // Endocrine Today;3/10/2008, Vol. 6 Issue 4, p36 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the zotarolimus-eluting stent for treating patients with narrowed coronary arteries. The stent had comparable safety and efficacy profile with a paclitaxel-eluting stent and a sirolimus-eluting stent during...

  • The use of percutaneous coronary intervention in black and white veterans with acute myocardial infarction. Maynard, Charles; Sun, Haili; Lowy, Elliott; Sales, Anne E.; Fihn, Stephan D. // BMC Health Services Research;2006, Vol. 6, p107 

    Background: It is uncertain whether black white differences in the use of percutaneous coronary intervention (PCI) persist in the era of drug eluting stents. The purpose of this study is to determine if black veterans with acute myocardial infarction (AMI) are less likely to receive PCI than...

  • A Prospective Trial of Ayurveda for Coronary Heart Disease: A Pilot Study. DuBroff, Robert; Lad, Vasant; Murray-Krezan, Cristina // Alternative Therapies in Health & Medicine;Sep/Oct2015, Vol. 21 Issue 5, p52 

    Context: Coronary heart disease is the leading cause of death worldwide, and its incidence is rapidly accelerating in developing nations. Patients often search for therapies that are alternatives to traditional treatments, such as heart medicines, coronary bypass surgery, or...

  • TCT 2008 notebook.  // Medical Device Daily;10/14/2008, Vol. 12 Issue 218, p2 

    The article reports on data presented by Abbott from 30 patients in its clinical trial, demonstrating that its bioabsorbable drug-eluting stent (DES) successfully treated coronary artery disease and was absorbed into the walls of treated arteries within two years. It was noted that patients who...

  • Cholesterol-lowering drug slows the progression of atherosclerosis and prevents MIs.  // Modern Medicine;Jan96, Vol. 64 Issue 1, p10 

    Reports on the effectiveness of pravastatin sodium (Pravachol), a cholesterol-lowering drug for slowing down the progression of coronary atherosclerosis and prevention of myocardial infarction in coronary artery disease patients (CAD). Monitoring levels of low density lipoproteins (LDL) and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics